Biomarker Market Trends

ID: MRFR/HC/1409-CR

200 Pages

Rahul Gotadki

July 2025

Biomarkers Market Research Report By Type (Predictive Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Research Biomarkers), By Application (Oncology, Cardiovascular, Neurology, Infectious Diseases, Autoimmune Diseases), By Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Mass Spectrometry, PCR Technologies), By End-use (Pharmaceutical Companies, Clinical Laboratories, Research Institutions, Diagnostic Laboratories), and By Regional (North America, Europe, South America, Asia Pacific,... read more

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Biomarker Market

The biomarkers market is undergoing substantial growth and transformation, driven by advancements in medical research, diagnostic technologies, and the shift towards personalized medicine. The trends are a reflection of the growing role played by biomarkers in health care for early detection, personalized treatment as well as monitoring effectiveness. The convergence of biomarkers into personalized medicine approaches is also one major trend in the biom markers market. Biomarkers permit personalized treatments based on individual patient characteristics, maximizing therapeutic results while minimizing side effects. Currently, a growing interest in the development and use of biomarkers for oncology is observed within the market. These biomarkers are helpful in cancer diagnosis, prognosis and treatment selection decisions leading to precision therapies. The advent of liquid biopsy as a novel technology is revolutionizing the cancer diagnostics. Liquid biopsies which use bodily fluids to test for the presence of pertinent markers, are a less invasive and more readily available approach that permits early detection monitoring numerous other cancer types. The use of biomarkers in regards to diagnosis and monitoring disorders is increasingly getting acceptance from the realm of neurology. Biomarkers are assisting in early diagnosis and also giving an insight into the progression of these diseases from Alzheimer’s to Parkinson. The focus on cardiovascular biomarkers continues to increase in heart health and assessing risks for other forms of cardio complexes. These biomarkers have a significant impact on the field of preventative medicine which allows early intervention and individual approach to cardiovascular disease management. The fact that the entire world has had to start focusing its attention on infectious diseases, combined with events such as COVID-19 pandemic have hastened implementation and utilization of biomarker for diagnosis infections. Effective disease control requires an urgent and precise detection mechanism through biomarkers. The point-of –care testing trend has a positive impact on the biomarkers market. The point-of-care biomarker testing provides immediate results in different medical facility settings, which is an effective approach for timely decision making that improves patient outcomes especially during emergencies. The application of artificial intelligence in biomarker research and analysis is constantly gaining momentum. AI significantly improves the process of interpreting biomarker data, identifies complex patterns that enable new discoveries in order to find novel and more accurate diagnostic procedures. Biomarkers are playing a significant role in the development of drugs. They help in patient stratification, managing response to treatment and predicting adverse effects. Biomarker data has enabled pharmaceutical companies to fast track clinical trials, enabling effective drug development. A key focus is the reliability and consistency of biomarker data. Standardized protocols for biomarker validation are currently being developed, overcoming issues with assay variability and guaranteeing the replicability of results within different laboratories. The biomarkers market is experiencing significant collaborations and partnerships among diagnostic companies, research centres, and healthcare providers. Such collaborative initiatives help in harnessing resources, sharing skills expertise and hastening the implementation of biomarker-based diagnostics innovation. The biomarkers market is driven by regulatory agencies. In order to achieve the utmost quality of biomarker-based diagnostics, regulatory guidelines should be provided for development and validation as well as use within clinical practice. The biomarkers market is gaining pace worldwide owing to the increasing incidence of chronic diseases, increased healthcare investments and rising demand for personalized medicine. New economies are gaining prominence in the biomarkers market due to investment made on healthcare infrastructure and research facilities.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the current valuation of the Biomarkers Market in 2025?

The Biomarkers Market is valued at approximately 60.66 USD Billion in 2024, and it is expected to grow significantly in the coming years.

What is the projected market size for the Biomarkers Market by 2035?

The market is projected to reach approximately 171.69 USD Billion by 2035, indicating substantial growth.

What is the expected CAGR for the Biomarkers Market during the forecast period 2025 - 2035?

The expected CAGR for the Biomarkers Market during the forecast period 2025 - 2035 is 9.92%.

Which segment of biomarkers is projected to have the highest valuation by 2035?

The Diagnostic Biomarkers segment is projected to reach approximately 51.1 USD Billion by 2035, making it a leading segment.

How do predictive biomarkers compare to prognostic biomarkers in terms of market valuation?

Predictive Biomarkers are expected to reach around 34.2 USD Billion by 2035, while Prognostic Biomarkers are projected at approximately 29.5 USD Billion.

What applications are driving growth in the Biomarkers Market?

Oncology is the leading application, projected to reach about 55.0 USD Billion by 2035, followed by Cardiovascular applications at 40.0 USD Billion.

Which technology segment is anticipated to show significant growth in the Biomarkers Market?

Omics Technologies are expected to grow to approximately 45.0 USD Billion by 2035, indicating a strong trend in this area.

What role do pharmaceutical companies play in the Biomarkers Market?

Pharmaceutical Companies are projected to dominate the market with an expected valuation of around 69.0 USD Billion by 2035.

How do clinical laboratories contribute to the Biomarkers Market?

Clinical Laboratories are anticipated to reach a valuation of approximately 43.0 USD Billion by 2035, reflecting their critical role in the market.

Who are the key players in the Biomarkers Market?

Key players include Roche, Thermo Fisher Scientific, Abbott Laboratories, and Merck KGaA, among others, leading the market dynamics.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Biomarkers Market Size was estimated at 60.66 USD Billion in 2024. The Biomarkers industry is projected to grow from 66.68 USD Billion in 2025 to 171.69 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.92 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Biomarkers Market is experiencing robust growth driven by technological advancements and increasing demand for personalized medicine.

The rise of companion diagnostics is reshaping treatment protocols, particularly in oncology. Integration of artificial intelligence is enhancing the accuracy and efficiency of biomarker discovery. Expansion of biomarker applications is evident in both predictive and diagnostic contexts, with predictive biomarkers leading the market. The increasing prevalence of chronic diseases and advancements in genomic technologies are key drivers propelling market growth, especially in North America and the Asia-Pacific region.

Market Size & Forecast

2024 Market Size	60.66 (USD Billion)
2035 Market Size	171.69 (USD Billion)
CAGR (2025 - 2035)	9.92%
Largest Regional Market Share in 2024	North America

Major Players

Roche (CH), <a href="https://www.thermofisher.com/in/en/home/life-science/cancer-research/solid-tumor-research/biomarker-discovery.html">Thermo Fisher Scientific</a> (US), Abbott Laboratories (US), Merck KGaA (DE), Agilent Technologies (US), Bio-Rad Laboratories (US), Illumina (US), Qiagen (DE), PerkinElmer (US)

Market Trends

The Biomarkers Market is currently experiencing a transformative phase, characterized by rapid advancements in technology and an increasing emphasis on personalized medicine. This evolution is driven by the growing recognition of biomarkers as essential tools for disease diagnosis, prognosis, and treatment monitoring. As healthcare systems worldwide strive for more efficient and effective patient care, the integration of biomarkers into clinical practice appears to be gaining momentum. Furthermore, the rise of precision medicine is likely to enhance the demand for biomarker-based solutions, as they enable tailored therapeutic approaches that align with individual patient profiles. In addition to technological advancements, regulatory frameworks are evolving to accommodate the complexities associated with biomarker development and application. This shift may facilitate faster approvals and market entry for innovative biomarker tests, thereby expanding their accessibility to healthcare providers and patients alike. Moreover, collaborations between academic institutions, biotechnology firms, and pharmaceutical companies are becoming increasingly common, fostering an environment conducive to innovation. As the Biomarkers Market continues to mature, it seems poised for sustained growth, driven by ongoing research and development efforts aimed at uncovering new biomarkers and their potential applications in various therapeutic areas.

Rise of Companion Diagnostics

The Biomarkers Market is witnessing a notable increase in the adoption of companion diagnostics. These tests are designed to identify patients who are most likely to benefit from specific therapies, thereby enhancing treatment efficacy. This trend reflects a broader shift towards personalized medicine, where therapies are tailored to individual patient characteristics, potentially improving outcomes and minimizing adverse effects.

Integration of Artificial Intelligence

The integration of artificial intelligence (AI) into biomarker discovery and analysis is emerging as a significant trend. AI technologies are being utilized to process vast amounts of biological data, enabling researchers to identify novel biomarkers more efficiently. This advancement may lead to quicker insights and a deeper understanding of disease mechanisms, ultimately accelerating the development of targeted therapies.

Expansion of Biomarker Market Applications

The applications of biomarkers are expanding beyond traditional areas such as oncology. There is a growing interest in utilizing biomarkers for various conditions, including cardiovascular diseases, neurological disorders, and infectious diseases. This diversification suggests a broader recognition of the potential of biomarkers to enhance diagnostic accuracy and treatment strategies across multiple therapeutic domains.

Biomarker Market Market Drivers

Advancements in Genomic Technologies

Technological advancements in genomic sequencing and analysis are propelling the Biomarkers Market forward. Innovations such as next-generation sequencing (NGS) and CRISPR technology have revolutionized the way biomarkers are identified and utilized in clinical settings. These technologies enable researchers to analyze vast amounts of genetic data quickly and accurately, facilitating the discovery of novel biomarkers for various diseases. The integration of these advanced technologies is expected to enhance the efficiency of biomarker development processes, thereby reducing time-to-market for new diagnostic tests. As a result, the Biomarkers Market is likely to witness substantial growth, with the genomic biomarker segment anticipated to account for a significant share of the overall market by 2025. This trend underscores the importance of continuous investment in research and development within the biomarker domain.

Growing Demand for Personalized Medicine

The shift towards personalized medicine is a significant driver of the Biomarkers Market. As healthcare evolves, there is an increasing recognition of the need for tailored treatment approaches that consider individual patient characteristics. Biomarkers serve as essential tools in this paradigm, enabling healthcare providers to select the most effective therapies based on a patient's unique biological profile. This trend is reflected in the rising number of biomarker-based companion diagnostics, which are designed to identify patients who are most likely to benefit from specific treatments. The market for personalized medicine is projected to grow substantially, with estimates suggesting it could reach over 2 trillion USD by 2025. This growth is likely to further stimulate the Biomarkers Market, as the demand for innovative diagnostic solutions continues to rise.

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a primary driver of the Biomarkers Market. As these conditions become more prevalent, the demand for effective diagnostic tools and personalized treatment options intensifies. Biomarkers play a crucial role in early detection and monitoring of these diseases, thereby enhancing patient outcomes. According to recent estimates, the market for biomarkers is projected to reach approximately 60 billion USD by 2026, reflecting a compound annual growth rate of around 12%. This growth is largely attributed to the increasing focus on precision medicine, which relies heavily on biomarker identification and validation. Consequently, the Biomarkers Market is expected to expand significantly as healthcare providers seek innovative solutions to manage chronic diseases.

Regulatory Support for Biomarker Development

Regulatory agencies are increasingly recognizing the importance of biomarkers in drug development and patient care, which is positively impacting the Biomarkers Market. Initiatives aimed at streamlining the approval process for biomarker-based diagnostics are being implemented, thereby encouraging innovation and investment in this field. For instance, the FDA has established guidelines for the development and validation of biomarkers, which facilitate their integration into clinical practice. This regulatory support not only enhances the credibility of biomarker applications but also fosters collaboration between industry stakeholders and regulatory bodies. As a result, the Biomarkers Market is likely to experience accelerated growth, with more companies entering the market to develop novel biomarker solutions that meet regulatory standards.

Rising Investment in Research and Development

Investment in research and development (R&D) within the biomarker sector is a crucial driver of the Biomarkers Market. Increased funding from both public and private sectors is enabling researchers to explore new biomarker candidates and develop innovative diagnostic tools. This influx of capital is particularly evident in the fields of oncology and rare diseases, where the need for effective biomarkers is paramount. According to recent reports, R&D spending in the biomarker space is expected to exceed 10 billion USD by 2025, reflecting a growing commitment to advancing biomarker science. This trend is likely to result in the discovery of novel biomarkers that can improve disease detection and treatment, thereby further propelling the Biomarkers Market.

Market Segment Insights

By Type: Predictive Biomarkers (Largest) vs. Diagnostic Biomarkers (Fastest-Growing)

The Biomarkers Market exhibits a diverse distribution among the different types of biomarkers. Predictive biomarkers currently hold the largest share within this segment, serving as essential tools in anticipating patient responses to therapeutic interventions. Following close behind, diagnostic biomarkers are emerging as a critical component in clinical settings, facilitating the identification of diseases at earlier stages.

Biomarkers: Predictive (Dominant) vs. Diagnostic (Emerging)

Predictive biomarkers are critical in shaping personalized medicine as they provide insights into the likely response of a patient to treatment protocols, enhancing clinical decision-making. This segment thrives on advancements in genetic and molecular profiling techniques. In contrast, diagnostic biomarkers are rapidly gaining traction due to their pivotal role in early disease detection and monitoring. Their emergence is driven by the increasing focus on precision medicine and the growing prevalence of chronic diseases, thus positioning them for significant growth in the near future.

By Application: Oncology (Largest) vs. Neurology (Fastest-Growing)

In the Biomarkers Market, oncology holds the dominant share, driven by the increasing prevalence of cancer and advancements in diagnostic technologies. The segments of cardiovascular, neurology, infectious diseases, and autoimmune diseases also play significant roles; however, their market shares are comparatively smaller. The demand for targeted therapies and <a href="https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937">personalized medicine</a> continues to enhance the role of biomarkers in guiding treatment decisions within oncology, placing it at the forefront of the market.

Oncology: Dominant vs. Neurology: Emerging

Oncology is a well-established sector in the Biomarkers Market, recognized for its critical role in cancer diagnostics and treatment. The segment benefits from robust research and development, alongside increasing investments aimed at improving patient outcomes through precision medicine. Conversely, neurology is emerging rapidly, largely driven by rising awareness of neurological disorders and innovations in biomarker identification. As neurodegenerative diseases like Alzheimer's continue to affect larger populations, the focus on neurological biomarkers is intensifying, pointing towards a promising growth trajectory for this segment.

By Technology: Omics Technologies (Largest) vs. Bioinformatics (Fastest-Growing)

The Biomarkers Market exhibits a diverse distribution of technology segments, with Omics Technologies holding the largest share. This segment encompasses genomics, proteomics, and metabolomics, playing a pivotal role in biomarker discovery and validation. In contrast, Bioinformatics is emerging as the fastest-growing segment, driven by the increasing need for data analysis in biomarker research. The integration of advanced computational tools in bioinformatics accelerates the analysis and interpretation of complex biological data generated through various omics approaches.

Omics Technologies: Dominant vs. Bioinformatics: Emerging

Omics Technologies is characterized by its comprehensive approaches to understanding biological processes at a molecular level, positioning it as the dominant segment in the Biomarkers Market. This segment includes various technologies that facilitate the study of the genome, proteome, and metabolome, providing critical insights for biomarker identification. Conversely, Bioinformatics represents an emerging segment that leverages computational power to analyze vast datasets, driven by the need for precision medicine. Its growth is fueled by advancements in machine learning and data analytics, essential for translating omics data into actionable insights, making it instrumental in the future of biomarker research.

By End-use: Pharmaceutical Companies (Largest) vs. Clinical Laboratories (Fastest-Growing)

In the Biomarkers Market, the end-use segment is significantly dominated by pharmaceutical companies, which hold a substantial share due to their extensive research and development activities. These companies utilize biomarkers for drug discovery, development, and personalized medicine, thereby driving a large portion of the market. Conversely, clinical laboratories are emerging rapidly as a critical component of the market. Their role in the development and application of biomarkers in diagnostics and patient management is increasingly recognized, allowing them to capture a growing share in the sector.

Pharmaceutical Companies (Dominant) vs. Clinical Laboratories (Emerging)

Pharmaceutical companies are at the forefront of the Biomarkers Market, leveraging biomarkers to enhance drug efficacy and safety profiles through targeted therapies. Their investment in biopharmaceuticals and personalized medicine continues to grow, solidifying their dominant market position. On the other hand, clinical laboratories are becoming increasingly vital as the demand for precise diagnostics rises. They focus on rapidly integrating biomarker technologies into routine testing, which allows for real-time patient monitoring and treatment adjustments. The synergy between pharmaceutical advances and clinical laboratory capabilities positions them uniquely to meet the evolving healthcare landscape.

Get more detailed insights about Biomarkers Market Research Report - Global Forecast till 2035

Regional Insights

The Biomarkers Market experienced substantial growth across various regions. North America led the market, holding a significant position with a valuation of 18.5 USD Billion, expected to grow to 37.5 USD Billion by 2035, reflecting its dominance in research and innovation.

Europe followed closely with a value of 12.5 USD Billion in 2024, anticipated to reach 25.5 USD Billion, supported by advancements in healthcare and regulatory frameworks. The Asia Pacific region accounted for 7.5 USD Billion in 2024, growing to 15.0 USD Billion, driven by increasing healthcare expenditure and a rising population.

South America, with a market value of 2.5 USD Billion, is projected to grow to 5.0 USD Billion as healthcare access improves. The Middle East and Africa segment was valued at 2.0 USD Billion, expected to reach 3.7 USD Billion, influenced by growing awareness of personalized medicine.

These regional insights emphasized the Biomarkers Market's segmentation and highlighted the opportunities for growth in different geographical areas, reflecting trends in healthcare advancements and the demand for innovative solutions.

Biomarkers Market Regional Insights

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Key Players and Competitive Insights

The Biomarkers Market has evolved significantly over the last few years, driven by advancements in technology and increasing demand for personalized medicine. Competitive insights in this market reveal a landscape filled with collaboration, innovation, and strategic partnerships among key players.

Companies are leveraging research and development to enhance their product offerings and maintain their competitive edge. The market is characterized by various segments based on types, applications, and countries, leading to diverse competition and strategic positioning.

The emphasis on diagnostic solutions, drug development, and targeted therapies has stimulated growth, pushing major players to adopt aggressive marketing and distribution strategies tailored to different geographic regions.

Novartis has established a substantial presence in the Biomarkers Market through its robust pipeline of biomarker development initiatives. The company focuses on integrating biomarkers into its drug discovery processes to enhance patient selection, improve treatment outcomes, and minimize adverse effects.

The strengths of Novartis in this domain lie in its extensive research capabilities, collaborations with academic institutions and biotechnology firms, and a strong portfolio of innovative therapies. Novartis's commitment to advancing biomarker research underscores its role in developing precision medicine, amplifying its influence in the global healthcare landscape.

Its strategic focus on rare diseases and oncology has positioned the company as a leader in utilizing biomarkers for therapeutic advancements, contributing significantly to its overall growth and market competitiveness.

Thermo Fisher Scientific plays a crucial role in the Biomarkers Market, primarily known for its comprehensive range of analytical instruments, reagents, and consumables that support biomarker discovery and validation.

The company’s significant strengths include its extensive product portfolio designed for biomarker research, including technologies for gene expression analysis, mass spectrometry, and next-generation sequencing.

Thermo Fisher Scientific has made strategic moves through a series of mergers and acquisitions to expand its capabilities and enhance market presence globally. These integrations have allowed the company to offer integrated solutions that streamline biomarker research, thereby increasing efficiency and reliability in biopharmaceutical applications.

Its commitment to innovation and customer support ensures Thermo Fisher Scientific remains a vital contributor to the evolving landscape of biomarkers, reinforcing its competitive stance within the industry on a global scale.

Key Companies in the Biomarker Market market include

Industry Developments

The Elecsys PRO-C3 test, created in partnership with Nordic Bioscience, was approved by the FDA in May 2025 by F. Hoffmann-La Roche Ltd. to evaluate the degree of liver fibrosis in patients with steatotic liver disease linked to metabolic dysfunction.

Roche also introduced the VENTANA MET (SP44) RxDx Assay in May 2025, which is intended to determine which patients with non-small cell lung cancer are suitable for targeted MET inhibitor treatments. By completing the purchase of SYNLAB's clinical diagnostics business in Spain in April 2025, Eurofins Scientific greatly increased its capacity for molecular diagnostics and biomarker validation.

Ignite Biomedical and Liquid Biosciences formed a strategic alliance in April 2025 to leverage AI-driven bioinformatics systems to find and verify new biomarkers for substance use disorders. Thermo Fisher Scientific and the UK Biobank Pharma proteome Project joined forces in January 2025 to fund the biggest proteome project in the world devoted to biomarker validation and development.

To enhance early identification and risk stratification in Alzheimer's disease, QIAGEN and Eli Lilly announced in September 2024 that they would be working together to create a QIAstat-Dx in vitro diagnostic panel for APOE genotyping.

Future Outlook

Biomarker Market Future Outlook

The Biomarkers Market is projected to grow at a 9.92% CAGR from 2024 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising demand for early disease detection.

New opportunities lie in:

Development of companion diagnostics for targeted therapies.Expansion of biomarker-based clinical trials for drug development.Integration of AI in biomarker discovery and validation processes.

By 2035, the Biomarkers Market is expected to achieve substantial growth, reflecting its critical role in healthcare innovation.

Market Segmentation

Biomarker Market Type Outlook

Predictive Biomarkers
Diagnostic Biomarkers
Prognostic Biomarkers
Pharmacodynamic Biomarkers
Research Biomarkers

Biomarker Market End-use Outlook

Pharmaceutical Companies
Clinical Laboratories
Research Institutions
Diagnostic Laboratories

Biomarker Market Technology Outlook

Omics Technologies
Imaging Technologies
Bioinformatics
Mass Spectrometry
PCR Technologies

Biomarker Market Application Outlook

Oncology
Cardiovascular
Neurology
Infectious Diseases
Autoimmune Diseases

Report Scope

MARKET SIZE 2024	60.66(USD Billion)
MARKET SIZE 2025	66.68(USD Billion)
MARKET SIZE 2035	171.69(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.92% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in personalized medicine drive demand for innovative biomarkers in diagnostics and therapeutics.
Key Market Dynamics	Rising demand for personalized medicine drives innovation and competition in the biomarkers market.
Countries Covered	North America, Europe, APAC, South America, MEA